We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DHR:NYSEDanaher Corporation Analysis

Data as of 2026-05-25 - not real-time

$172.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Danaher’s stock trades around $172, just above its 20‑day SMA (≈$171.8) but comfortably below the 50‑day SMA (≈$182.9), signaling a short‑term bearish bias despite a bullish MACD histogram and a neutral RSI near 45. High 30‑day volatility (~29%) and a bearish trend direction compound the downside risk, while the beta of ~0.75 suggests the stock moves less than the market overall. Fundamentally, the company appears overvalued, with a trailing P/E of 33× versus the industry average of 27× and a DCF fair‑value estimate of roughly $79, far below the current price.
Recent earnings disappointed investors, yet the business continues to generate strong cash flow, a low payout ratio (~26%) and a sustainable dividend yield of 0.9%. Forward EPS is projected to rise to $9.09, cutting the forward P/E to ~19× and supporting a 44% upside target from analysts. The combination of solid fundamentals, a low‑beta defensive profile, and a strong‑buy consensus suggests a medium‑term buying case, while short‑term caution remains warranted due to technical weakness and valuation concerns.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Price below 50‑day SMA indicating bearish momentum
  • Recent earnings miss dampening short‑term sentiment
  • High volatility and proximity to support level

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Forward EPS growth and reduced forward P/E around 19×
  • Strong cash generation and sustainable dividend
  • Analyst consensus strong‑buy with ~44% upside potential

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Significant valuation gap between market price and DCF fair value
  • Stable business model with low beta and defensive cash flow
  • Ongoing regulatory and geopolitical exposure

Key Metrics & Analysis

Financial Health

Revenue Growth3.70%
Profit Margin14.89%
P/E Ratio33.3
ROE7.08%
ROA4.19%
Debt/Equity37.17
P/B Ratio2.3
Op. Cash Flow$6.4B
Free Cash Flow$4.6B
Industry P/E27.6

Technical Analysis

TrendBearish
RSI44.5
Support$160.93
Resistance$183.00
MA 20$171.77
MA 50$182.91
MA 200$206.57
MACDBullish
VolumeStable
Fear & Greed Index91.8

Valuation

Fair Value$78.75
Target Price$247.83
Upside/Downside44.08%
GradeOvervalued
TypeBlend
Dividend Yield0.93%

Risk Assessment

Beta0.75
Volatility28.89%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.